From CP’s message earlier today According to the trial description at clinicaltrials.gov ( http://www.clinicaltrials.gov/ct/show/NCT00408226 ), the trial will "... determine the antitumor activity, based on the objective response rate and median Progression Free Survival ("PFS")...".
Having reread today's release, I believe they are referring a more narrow definition. From today’s press release Patients were subsequently enrolled into the Phase 2 portion where the primary endpoint was tumor response.
Market Data 
Markets 
AI
